Exelixis (EXEL) Enterprise Value (2010 - 2026)
Exelixis (EXEL) posted quarterly Enterprise Value of -$777.2 million for Q2 2026, up 24.64% year-over-year from -$623.6 million in Q2 2025, and up 26.62% quarter-over-quarter from -$1.1 billion in Q1 2026.
Exelixis (EXEL) Enterprise Value (2010 - 2026) Analysis & Trends
Exelixis' Enterprise Value history runs 17 years deep, the most recent figure standing at -$777.2 million for Q2 2026.
- In Q2 2026, Enterprise Value rose 24.64% year-over-year to -$777.2 million; the TTM figure through Apr 2026 stood at -$777.2 million (up 24.64% YoY), while the FY2026 annual figure was -$1.1 billion, up 4.7% from the prior year.
- Enterprise Value for Q2 2026 stood at -$777.2 million, up from -$1.1 billion in the prior quarter.
- The five-year high for Enterprise Value was -$777.2 million in Q2 2026, with the low at -$1.6 billion in Q2 2022.
- The 5-year median for Enterprise Value is -$1.1 billion (2023), against an average of -$1.2 billion.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 32.46% in 2022, then rose 28.68% in 2023.
- Exelixis' Enterprise Value stood at -$1.3 billion in 2022, then grew by 23.93% to -$995.3 million in 2023, then retreated by 19.48% to -$1.2 billion in 2024, then gained by 16.87% to -$988.5 million in 2025, then advanced by 21.38% to -$777.2 million in 2026.
- Business Quant data shows EXEL's Enterprise Value at -$777.2 million in Q2 2026, -$1.1 billion in Q1 2026, and -$988.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | -839.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | -839.39 Mn |
| Apr 3, 2026 | -777.21 Mn |
| Jan 2, 2026 | -1.06 Bn |
| Oct 3, 2025 | -988.54 Mn |
| Jul 4, 2025 | -791.10 Mn |
| Apr 4, 2025 | -1.03 Bn |
| Jan 3, 2025 | -1.11 Bn |
| Sep 27, 2024 | -1.19 Bn |
| Jun 28, 2024 | -1.00 Bn |
| Mar 29, 2024 | -963.26 Mn |
| Dec 29, 2023 | -995.30 Mn |
| Sep 29, 2023 | -1.10 Bn |
| Jun 30, 2023 | -1.27 Bn |
| Mar 31, 2023 | -1.31 Bn |
| Dec 30, 2022 | -1.31 Bn |
| Sep 30, 2022 | -1.55 Bn |
| Jul 1, 2022 | -1.53 Bn |
| Apr 1, 2022 | -1.57 Bn |
| Dec 31, 2021 | -1.47 Bn |
| Oct 1, 2021 | -1.40 Bn |